Compugen Ltd., of Tel Aviv, Israel, initiated a multiyear research collaboration with Johns Hopkins University, School of Medicine, focusing on further evaluation of selected B7/CD28-like immune checkpoint candidates discovered by Compugen for the potential treatment of cancer.